Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Sino Biopharmaceutical ( (HK:1177) ) is now available.
Sino Biopharmaceutical Limited announced that its HER2-selective tyrosine kinase inhibitor, zongertinib, has been granted Breakthrough Therapeutic Designation by the Center for Drug Evaluation in China for treating unresectable or metastatic non-small cell lung cancer with HER2 mutations. This designation, supported by clinical trial results, highlights the potential of zongertinib to address the unmet need for targeted therapies in this patient population. The company’s strategic partnership with Boehringer Ingelheim aims to enhance cancer treatment options in China, leveraging both companies’ strengths to bring innovative oncology products to market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. The company, along with its subsidiaries, is involved in developing innovative oncology therapies, particularly targeting the Chinese market through strategic partnerships.
Average Trading Volume: 180,194,218
Technical Sentiment Signal: Buy
Current Market Cap: HK$141.5B
For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.